Skip to main content
. Author manuscript; available in PMC: 2014 Nov 21.
Published in final edited form as: J Clin Pharmacol. 2010 Nov 23;51(9):1264–1275. doi: 10.1177/0091270010382021

Table 2.

Clinical outcomes

Study
number
Ureaplasma
culture status
Status @
36 wk PMA
Timed O2
reduction test
performed
Results of
Timed O2
reduction test
Physiologic BPD
@ 36 wk PMA
1 Pos Died 56 d
2 Pos Alive,
SIMV
No Yes
3 Pos Alive, NC Yes Passed No
4 Pos Died 21 d
5* Pos Alive,
nCPAP
No Yes
6 Pos Alive, NC Yes Passed No
7 Pos Alive,
SIMV
No Yes
8** Pos Died 3 d

All
positives
3 deaths 2/5 2 3/5 (60%)

9 Neg Alive, NC Yes Passed No
10 Neg Alive, NC Yes Passed No
11 Neg Alive, NC Yes Passed No
12 Neg Transferred,
NC
No Yes
13 Neg Alive, room
air
No No
14 Neg Alive, NC Yes Passed No

All
negatives
0 deaths 4/6 4 1/6 (17%)

Total 3 deaths 6 6 4/14 (29%)
*

received 2 additional doses azithromycin (protocol violation);

**

withdrawn prior to dosing due to clinical deterioration

PMA: post-menstrual age

NC: nasal cannula; nCPAP: nasal continuous positive pressure; SIMV: synchronized intermittent mandatory ventilation